{"id":259176,"date":"2026-07-13T16:47:43","date_gmt":"2026-07-13T13:47:43","guid":{"rendered":"https:\/\/1kitap1.com\/en\/drugs-in-palliative-care-3rd-edition-andrew-dickman\/"},"modified":"2026-07-13T16:47:43","modified_gmt":"2026-07-13T13:47:43","slug":"drugs-in-palliative-care-3rd-edition-andrew-dickman","status":"publish","type":"post","link":"https:\/\/1kitap1.com\/en\/drugs-in-palliative-care-3rd-edition-andrew-dickman\/","title":{"rendered":"Drugs In Palliative Care 3rd Edition – Andrew Dickman"},"content":{"rendered":"
\"<\/figure>\n

\u2022 Fluconazole\u2014\u200bincreases plasma concentration of glipizide. \u2022 Miconazole\u2014\u200bcontraindicated for use (enhanced hypoglycaemic effect, presumably CYP2C9 inhibition). \u2022 Warfarin\u2014\u200bincreased risk of hypoglycaemia. Pharmacodynamic \u2022 ACE-\u200bIs\u2014\u200bincreased risk of hypoglycaemia. \u2022 \u03b22-\u200bagonists\u2014\u200bhypoglycaemic effect may be antagonized. \u2022 Corticosteroids\u2014\u200bhypoglycaemic effect antagonized. \u2022 Diuretics\u2014\u200bhypoglycaemic effect may be antagonized. \u2022 SSRIs\u2014\u200bincreased risk of hypoglycaemia. G Dose \u2022 Initial dose 2.5mg to \u200b5mg PO OD, taken before breakfast or lunch.<\/p>\n

The dose can be increased as necessary by 2.5mg to 5mg PO OD over several days. The maximum recommended single dose is \ue0005mg PO daily; doses above \ue0005mg should be divided. The maximum daily dose is 20mg. Dose adjustments Elderly \u2022 Usual adult doses can be used, although the elderly are more susceptible to adverse effects. The initial dose should be 2.5mg PO OD and should be titrated to effect. Hepatic\/\u200brenal impairment \u2022 Care should be exercised in patients with hepatic and\/\u200bor renal impairment and a smaller initial dose should be used, with careful patient monitoring.<\/p>\n

Dose should be titrated to effect. \u2022 Glipizide should be avoided in patients with severe hepatic and\/\u200bor renal impairment and insulin treatment should be initiated. Additional information \u2022 Tablets can be crushed and dispersed in water immediately prior to administration if necessary. u Pharmacology Glipizide is a sulfonylurea which stimulates \u03b2-\u200bcells of the islets of Langerhans in the pancreas to release insulin. It also enhances peripheral insulin sensi- tivity. It restores the first peak of insulin secretion in response to glucose and increases the second phase of insulin secretion.<\/p>\n

The metabolism of many sulfonylureas is catalysed by CYP2C9. Glyceryl trinitrate Glyceryl trinitrate Rectogesic\u00ae (POM) Rectal ointment: GTN 0.4% (30 g). Generic (P) Sublingual tablet: 300 micrograms (\ue00000); 500 micrograms (\ue00000); 600 micrograms (\ue00000). NB\u2014\u200btablets should be stored in the original container and discarded 8 weeks from opening. Proprietary formulations are available (see current BNF). Other formulations are available (e.g. parenteral, transdermal) but are not dis- cussed (see current BNF). Indications \u2022 Anal fissure.<\/p>\n

\u2022 \u2722Smooth muscle spasm pain (e.g. anus, oesophagus, rectum). \u2022 Angina (not discussed). Contraindications and cautions \u2022 Contraindicated for use in the following: \u2013 anaemia (severe) \u2013 aortic and\/\u200bor mitral stenosis \u2013 closed-\u200bangle glaucoma \u2013 concomitant use with phosphodiesterase inhibitors (e.g. sildenafil, tadalafil, vardenafil) \u2013 constrictive pericarditis \u2013 hypertrophic obstructive cardiomyopathy \u2013 hypotension \u2013 hypovolaemia \u2013 migraine or recurrent headache \u2013 raised intracranial pressure.<\/p>\n

\u2022 Use with caution in patients with: \u2013 hypothermia \u2013 hypothyroidism \u2013 malnutrition \u2013 recent history of myocardial infarction \u2013 severe hepatic impairment \u2013 severe renal impairment \u2013 susceptibility to angle-\u200bclosure glaucoma. \u2022 Note that transdermal patches that contain metal must be removed before MRI (to avoid burns).<\/p>\n

\n

Consultant Pharmacist \u2013\u200b Palliative Care Academic Palliative and End of Life Care Centre Liverpool University Hospitals NHS Foundation Trust Liverpool UK With contribution by James Baker MPharm PgDip Principal Pharmacist for Medicines Optimisation Stepping Hill Hospital Stockport NHS Foundation Trust Stockport UK Great Clarendon Street, Oxford, OX2 6DP, United Kingdom Oxford University Press is a department of the University of Oxford.<\/p>\n

It furthers the University\u2019s objective of excellence in research, scholarship, and education by publishing worldwide. Oxford is a registered trade mark of Oxford University Press in the UK and in certain other countries \u00a9 Andrew Dickman 2023 The moral rights of the authors have been asserted First Edition published in 20\ue0000 Second Edition published in 20\ue0002 Third Edition published in 2023 Impression: \ue000 All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, without the prior permission in writing of Oxford University Press, or as expressly permitted by law, by licence or under terms agreed with the appropriate reprographics rights organization.<\/p>\n

Enquiries concerning reproduction outside the scope of the above should be sent to the Rights Department, Oxford University Press, at the address above You must not circulate this work in any other form and you must impose this same condition on any acquirer Published in the United States of America by Oxford University Press \ue00098 Madison Avenue, New York, NY \ue00000\ue0006, United States of America British Library Cataloguing in Publication Data Data available Library of Congress Control Number: 202294\ue000535 ISBN 978\u2013\u200b0\u2013\u200b\ue0009\u2013\u200b874640\u2013\u200b9 DOI: \ue0000.\ue000093\/\u200bmed\/\u200b9780\ue00098746409.00\ue000.000\ue000 Printed in the UK by Ashford Colour Press Ltd, Gosport, Hampshire Oxford University Press makes no representation, express or implied, that the drug dosages in this book are correct.<\/p>\n

Readers must therefore always check the product information and clinical procedures with the most up-\u200bto-\u200bdate published product information and data sheets provided by the manufacturers and the most recent codes of conduct and safety regulations. The authors and the publishers do not accept responsibility or legal liability for any errors in the text or for the misuse or misapplication of material in this work.<\/p>\n

Except where otherwise stated, drug dosages and recommendations are for the non-\u200bpregnant adult who is not breast-\u200bfeeding Some of the medication discussed in this book may not be available through normal channels and only available by special arrangements. Other examples used in research studies and recommended in international guidelines are unlicensed or may be subject to being used outside of their licensed dosage ranges within the UK. We suggest consulting the BNF and local prescribing guidelines\/protocols before using unfamiliar medication.<\/p>\n<\/blockquote>\n

This is a short excerpt from the opening of “” by Unknown, quoted for review and introduction purposes. All rights belong to the copyright holders.<\/em><\/p>\n

\n
\n

Table of Contents<\/p>\nToggle<\/span><\/path><\/svg><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n